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Reacting to Antibiotic Allergies
Abstract
About 10-15% of all adults report that they are allergic to penicillin or other antibiotics, although the
accuracy and significance of these reports remain unclear. In the outpatient setting, clinicians often face
a dilemma in prescribing for patients with a history of an allergic reaction to antibiotics. Which drugs
should these patients avoid? Are these patients at increased risk for an allergic reaction to related drugs?
This Issue Brief summarizes several large studies that can help guide and improve the management of
patients with antibiotic allergies.
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Antibiotic allergies are
common, but the risk for
subsequent allergic
reactions is not known
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Reacting to Antibiotic Allergies
Editor’s note: About 10-15% of all adults report that they are allergic to
penicillin or other antibiotics, although the accuracy and significance of
these reports remain unclear. In the outpatient setting, clinicians often
face a dilemma in prescribing for patients with a history of an allergic
reaction to antibiotics. Which drugs should these patients avoid? Are
these patients at increased risk for an allergic reaction to related drugs?
This Issue Brief summarizes several large studies that can help guide and
improve the management of patients with antibiotic allergies.

The discovery of antibiotics was one of the greatest medical advances of the modern
era. Since the 1940s, successive classes of antibiotics have been introduced to fight
bacterial infections and treat new or resistant organisms. These classes include
sulfonamides (“sulfa” drugs), followed by penicillins, aminoglycosides, tetracyclines,
cephalosporins, flouroquinolones, and macrolides.
• Antibiotics are the most commonly prescribed drugs today, and the most
common cause of drug-related allergies. While most allergic reactions involve
mild skin irritations, some reactions can be life-threatening.
• Prescribing for a patient with an antibiotic allergy is complicated by concern over
whether the patient has a related sensitivity to a different drug, a process known as
“cross-reactivity.” For example, patients allergic to penicillin may be allergic to
cephalosporins, which have structural similarities to penicillins.
• Both overestimating and underestimating the risk of allergic reactions can harm
patients. Overestimating the risk can lead to unnecessary use of more costly
antibiotics or selection of less effective drugs, and may contribute to the
development of drug-resistant microorganisms.

Large-scale studies shed
light on antibiotic allergies
in outpatient settings

To better understand the risk of antibiotic allergies in the outpatient setting, Strom
and colleagues used the General Practice Research Database (GPRD), a large
electronic database of primary care medical records and prescriptions in the United
Kingdom. The GPRD contains records from nearly 700 general practitioner
practices in England and Wales.
Continued on next page.

• Using the GPRD, the researchers sought to document the nature and prevalence
of allergic reactions and cross-reactivity among antibiotics. Previously, most of
the evidence about antibiotic allergies had come from small studies of hospital
patients, even though most antibiotics are prescribed in office settings.
• In each study, the researchers identified “allergic-like events” in the database that
occurred within 30 days after receipt of an antibiotic prescription. They used both
a narrow and broad definition of these events. The narrow definition included
diagnostic codes for rashes and hives, wheezing, unspecified allergic drug
reactions, and more serious reactions such as anaphylaxis. The broad definition
expanded the set of codes to include asthma, eczema, or an unspecified adverse
drug effect.
• One advantage of the study design is that it used diagnoses in the medical records
to identify an allergic reaction, rather than relying on patient reports. It is likely
that the true incidence of allergic reactions is higher than the rate ascertained by
the narrow definition, and lower than the rate ascertained by the broad definition.
However, the results in each study were similar using either definition, lending
credibility to the findings.

Allergy to sulfa antibiotics
may indicate a
predisposition to allergic
reactions to other drugs,
not just to those that are
sulfa-based

Sulfa antibiotics are no longer the first-line treatment for most infections, although
they are still used to treat urinary tract infections. However, non-antibiotic sulfa
drugs are widely used today to treat common conditions such as hypertension,
osteoarthritis, and diabetes. Clinicians have been concerned about cross-reactivity
between sulfa-based drugs, and whether non-antibiotic sulfa drugs are safe for
individuals with prior allergic reactions to sulfa antibiotics. To answer this question,
Strom and colleagues compared allergic reactions to other sulfa drugs in those who
did and did not have an allergic reaction to a sulfa antibiotic. They also examined
reactions to subsequent penicillins, a biochemically distinct class of antibiotic.
• The researchers identified 20,225 patients in the database who had received a
sulfa antibiotic and a subsequent non-antibiotic sulfa drug from 1987-1999.
Overall, 4.8% of patients (969) had an apparent allergic reaction (using the broad
definition) after receiving the initial sulfa antibiotic. Of these, 9.9% (96) had an
allergic reaction after subsequently receiving a sulfa non-antibiotic. Of the
patients who had no allergic reaction after a sulfa antibiotic, 315 (1.6%) had an
allergic reaction after a sulfa non-antibiotic. Adjusting for other factors, patients
with a history of allergies to sulfa antibiotics had nearly three times the risk of a
reaction to a non-antibiotic sulfa drug as those with no such history.
• However, when looking at patients who received a sulfa antibiotic and a
subsequent a penicillin, those with a prior reaction to a sulfa antibiotic had an
even greater risk of a reaction after receiving a penicillin. These patients had
nearly four times the risk of a reaction to penicillin than those without a history
of a reaction to a sulfa antibiotic.
• The researchers conclude that a history of allergy to sulfa antibiotics is a marker of
increased risk for allergies to subsequent drugs. This risk appears to be due to a
predisposition to allergic reactions rather than to cross-reactivity with sulfa-based
drugs.

Allergic reaction to
penicillin is less frequent
than previously thought;
second prescription after
an allergic-like event is
common, and rarely causes
problems

Based on case studies of inpatients, the overall frequency of penicillin allergy has
been reported to be about 2% per course, with the rate of recurrence upon reexposure to penicillin as high as 60%. The rate of anaphylaxis is estimated to be 1
for every 5,000-10,000 courses of penicillin. Apter and colleagues sought to
confirm these estimates in the GPRD, using the narrow definition of allergic-like
events.
• The researchers identified more than three million patients who had received at
least one penicillin prescription from 1987-2001. Of these, 6,212 (0.18%)
experienced an allergic-like event after the initial prescription.
• Sixty per cent of all patients received a second penicillin prescription at least 60
days later. Almost half—3,014 (48.5%)—of the patients who had had an allergic
reaction received a second prescription. Fifty-seven (1.9%) of these patients
experienced a second reaction to the antibiotic. Few of the reactions were serious;
none resulted in death. Hives accounted for about 75% of the events. Only one
patient had anaphylaxis after both prescriptions.
• More than two million patients who did not have a reaction to the initial
penicillin were given a second penicillin prescription. Of these, 3,452 (0.17%)
patients had a reaction to the second prescription. Adjusting for other factors,
patients with an initial reaction to penicillin were 9 times more likely to
experience a second reaction to penicillin, although the absolute risk is small—less
than 2%.
• The rate of anaphylaxis was much smaller than previously reported, and was
estimated to be between 8-16 per million penicillin prescriptions.

Cephalosporins are not
much more likely to cause
allergic reactions in
penicillin allergic patients
than any other antibiotic

Penicillins and cephalosporins have structural similarities, giving rise to concern
about cross-reactivity. Small studies have reported that up to 10% of patients who
are allergic to penicillin may experience a reaction to cephalosporins. Apter and
colleagues investigated the relationship between penicillin and cephalosporin allergy
in the GPRD, using the narrow definition. To distinguish cross-reactivity from a
general predisposition to allergic reactions, they also investigated reactions to
subsequent sulfa antibiotics.
• Of the more than three million patients receiving a penicillin prescription from
1987-2001, 534,810 received a subsequent cephalosporin at least 60 days later.
• About 1% of the 3,920 patients who had an allergic reaction after penicillin also
had reaction after the cephalosporin. This is 10 times greater than the risk of a
cephalosporin reaction in patients who did not have a reaction to penicillin.
However, in a separate analysis of patients receiving penicillin followed by a sulfa
antibiotic, patients who had a reaction following penicillin had 7 times the risk of
a reaction to a sulfa antibiotic. These results suggest that cross-reactivity does not
adequately explain the increased risk.
• Although the relative risk of a subsequent reaction is high, the absolute risk is very
small. For example, in patients with a previous penicillin reaction, the absolute
risk of anaphylaxis after a cephalosporin was less than 0.001%.
Continued on back.

POLICY IMPLICATIONS

These studies provide large-scale epidemiologic evidence about antibiotic allergies as
they are encountered in an outpatient setting. It sheds light on the relative and
absolute risks of allergic-like events, and clarifies the risk of cross-reactivity.
• Clinicians should recognize the importance of taking a careful history about
antibiotic allergies, given that prior events may be a marker for a general
predisposition to allergic reactions. However, concerns about cross-reactivity
between antibiotic drugs seem unwarranted. These data indicate that
cephalosporins can be considered for patients with penicillin allergy, and that
patients with an allergy to sulfa antibiotics do not need to be steered away from
sulfa-based drugs.
• In outpatient settings, the incidence of serious reactions to penicillin (such as
anaphylaxis) is much lower than previously reported, and represcription of
penicillin is much more frequent than anticipated.
• However, these results must be interpreted with caution in light of the
retrospective nature of the studies. Patients at risk for severe reactions may have
been underrepresented, and not all of the reactions patients experienced may have
been reported to their physician. Furthermore, the results apply only to
outpatients given oral antibiotics; the risks associated with intravenous
administration to inpatients may be much higher.
• Further research is needed to understand the mechanisms by which patients with
a history of allergic reactions to antibiotics are at increased risk for subsequent
reactions to unrelated compounds.
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